Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

CRISPR/Cas9 technology has revolutionised the ability of scientists to make genetically modified cells and animal models. Here, the authors make a Tet-On genetically modified mouse using the Streptococcus pyogenes Cas9 and demonstrate that it can be used for generation of mice with lung cancer.

Saved in:
Bibliographic Details
Main Authors: Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal, Frank Seeliger, Camilla Johansson, Abdel Wahad Bidar, Lukas Badertscher, Sandra Wimberger, Emma J. Davies, Elizabeth Hardaker, Carla P. Martins, Emily James, Therese Admyre, Amir Taheri-Ghahfarokhi, Jenna Bradley, Anna Schantz, Babak Alaeimahabadi, Maryam Clausen, Xiufeng Xu, Lorenz M. Mayr, Roberto Nitsch, Mohammad Bohlooly-Y, Simon T. Barry, Marcello Maresca
Format: article
Language:EN
Published: Nature Portfolio 2020
Subjects:
Science
Q
Online Access:https://doaj.org/article/8d05a4aa843b419591409ca746b331db
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CRISPR/Cas9 technology has revolutionised the ability of scientists to make genetically modified cells and animal models. Here, the authors make a Tet-On genetically modified mouse using the Streptococcus pyogenes Cas9 and demonstrate that it can be used for generation of mice with lung cancer.

Similar Items